Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2014, with the report dated July 10, 2014. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) in the company's Ordinary Shares, filed pursuant to Rule 13a-16 of the Securities Exchange Act of 1934 and Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by nine Directors and PDMRs on July 9, 2014, executed through the Company's ShareReward Plan. The transactions occurred at a price of 1,554.945 pence per Ordinary Share. Each individual acquired:
- 8 Ordinary Shares under the personal contribution element of the Plan.
- 8 Ordinary Shares under the matching element of the Plan (Company contribution).
The individuals involved are Sir Andrew Witty, Mr S Dingemans, Mr S M Bicknell, Mr R G Connor, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory notification of the share acquisitions listed above.
Investor Verification Checklist
- Verify the share price of 1,554.945 pence per Ordinary Share on July 9, 2014, against market data.
- Confirm the total number of shares acquired by each Director (16 shares per person) aligns with the ShareReward Plan rules.
- Check subsequent filings to ensure these transactions were properly reflected in the company's insider trading records.